New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia

(2019) Pitchai Balakumar et al.   Current Molecular Pharmacology

High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk

(2018) Peter P. Toth et al.   Journal of the American Heart Association

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

(2017) Mukul R. Jain et al.   LIVER INTERNATIONAL

Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial

(2016) A. O. Stirban et al.   DIABETES OBESITY & METABOLISM

Saroglitazar for the treatment of dyslipidemia in diabetic patients

(2015) Shashank R Joshi   EXPERT OPINION ON PHARMACOTHERAPY

Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence

(2015) Sosale Aravind Sosale et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus

(2014) A. Michael Lincoff et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence of Dyslipidemia in Urban and Rural India: The ICMR–INDIAB Study

(2014) Shashank R. Joshi et al.   PLoS One

A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)

(2013) Rajendrakumar H. Jani et al.   Diabetes Technology & Therapeutics

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update

(2013) Ž. Reiner   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dyslipidemia in type 2 diabetes mellitus

(2009) Arshag D Mooradian   Nature Reviews Endocrinology